Epstein Barr Virus clinical trials

Explore recruiting epstein barr virus clinical trials.

Recruiting epstein barr virus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epstein Barr Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

ATA129-EBV-205 An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)

Spain, Belgium, Austria, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant lymphoproliferative disorders - REPLY

France

Therapeutic use (Phase IV) EU CTIS Study details

Epstein Barr Virus trials by city

Epstein Barr Virus in Toronto Epstein Barr Virus in Vancouver Epstein Barr Virus in Montreal Epstein Barr Virus in Calgary Epstein Barr Virus in Edmonton Epstein Barr Virus in Ottawa Epstein Barr Virus in Winnipeg Epstein Barr Virus in Quebec City Epstein Barr Virus in Hamilton Epstein Barr Virus in Kitchener Epstein Barr Virus in London Epstein Barr Virus in Halifax Epstein Barr Virus in New York Epstein Barr Virus in Los Angeles Epstein Barr Virus in Chicago Epstein Barr Virus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease